Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 11, 2020
Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy☆C N Owen, A N Shoushtari, D Chauhan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 30, 2025
Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: a joint SITC and INMC effortJ S Deutsch, R A Scolyer, E Burton, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 6, 2017
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 studyG V Long, K T Flaherty, D Stroyakovskiy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 27, 2018
Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanomaM T Tetzlaff, J L Messina, J E Stein, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 21, 2023
Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trialsJ M Versluis, A M Menzies, K Sikorska, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 6, 2023
Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemiaS H Cass, J W D Tobin, Y D Seo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 2, 2021
Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanomaC N Owen, X Bai, T Quah, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2025
Pathological response calculation assessment remains accurate with reduced tumor bed examination after neoadjuvant immunotherapy in clinically detectable stage III melanomaR V Rawson, N G Maher, A M Menzies, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 21, 2021
Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanomaR V Rawson, C Adhikari, C Bierman, et al.
Nature Medicine|February 9, 2021
Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanomaE A Rozeman, E P Hoefsmit, I L M Reijers, et al.
Pageof 6